Skip to content
ANAVEX
ANAVEX
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
Search
  • HOME
  • ABOUT US
  • NEWS
  • PIPELINE
  • INVESTORS
    • Events
    • Share Data
    • Analyst Coverage
    • Code of Conduct
    • Investor Material
    • Presentations
  • JOIN US
View allAlzheimer's DiseaseAnavex2-73EventsNews ReleasesPDDPIPELINEPressRett Syndrome
Nov62019

Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome

November 6, 2019
Oct92019

Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease 

October 9, 2019
Oct22019

Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’s Disease

October 2, 2019
Sep272019

Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 Study

September 27, 2019
Sep262019

Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

September 26, 2019
Sep182019

Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference

September 18, 2019
Sep162019

Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

September 16, 2019
Sep52019

Anavex Life Sciences to Present at the Janney Healthcare Conference 2019

September 5, 2019
Sep42019

Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Rett Syndrome

September 4, 2019
Aug72019

 Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results and Provides Clinical Study Updates

August 7, 2019
Aug22019

Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday August 7th, 2019

August 2, 2019
Jul312019

Anavex Life Sciences Reports Recent Data Review by the Independent Data Safety Monitoring Board for its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patients with Rett Syndrome

July 31, 2019
123456…
7891011121314151617181920212223242526272829303132333435363738394041
42

ANAVEX® is a trademark of Anavex®Life Sciences Corp. - 2019 All Rights Reserved

Go to Top